Questioning the Role of Routine Liver Enzyme Monitoring in Statin Therapy

McPherson R Frolich J Fodor G Genest J . Canadian Cardiovascular Society position statement — recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913–27.

Law M Rudnicka AR . Statin safety: a systematic review. Am J Cardiol 2006;97:52C–60C.

Newman C Tsai J Szarek M Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61–7.

Repchinsky C , ed. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2008.

McKenney JM Davidson MH Jacobson TA Guyton JR . Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol 2006;97:89C–94C.

Ostapowicz G Fontana R Schiødt F Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947–54.

Uetrecht J . Idiosyncratic drug reactions: current understanding. Ann Rev Pharmacol Toxicol 2007;47:513–39.

Lee WM Senior JR . Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155–64.

Argo C Loria P Caldwell S Lonardo A . Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008;48:662–9.

Lewis JH . Hy's Law, the Rezulin Rule, and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006;15:221–9.

Lazo M Selvin E Clark JM . Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 2008;148:348–52.

FDA Working Group. PhRMA/FDA/AASLD. Drug-induced hepatotoxicity white paper: postmarketing considerations. PhRMA/FDA/AASLD: 2000;1–29. Available: www.fda.gov/CDER/livertox/postmarket.pdf (accessed October 29, 2008).

Chalasani N Aljadhey H Kesterson J Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287–92.

Smith C Bernstein L Davis R Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003;163:688–92.

Charles E Olson K Sandhoff B Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005;118:618–24.

Clarke A Mills P . Atorvastatin associated liver disease. Dig Liver Dis 2006;38:772–7.

Ahmad SR . US Food and Drug Administration Center for Drug Evaluation and Research. Memorandum: Consult: statins and hepatotoxicity. Available: www.fda.gov/ohrms/dockets/ac/00/backgrd/3622b2b_safety_review.pdf (accessed October 29, 2008).

Russo M Galanko J Shrestha R Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018–23.

Cohen D.E. Anania FA Chalasani N . An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C–81C.